| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Arjunolic acid does not have a specific pharmacological target in the traditional sense. Its biological effects are related to its antioxidant and anti-inflammatory properties. It scavenges free radicals such as DPPH. It modulates various signaling pathways involved in inflammation, oxidative stress, and cell survival. Its cardioprotective effects are attributed to its antioxidant and anti-inflammatory activities.
|
|---|---|
| ln Vitro |
In vitro, arjunolic acid scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. It demonstrates antioxidant activity in various cell-free assays. Its anti-inflammatory and anticancer activities have been demonstrated in cellular models. These in vitro activities confirm its diverse biological properties as a natural triterpenoid.
|
| ln Vivo |
In vivo, arjunolic acid displays protective effects during chemical-induced organ pathophysiology. It has cardioprotective properties and anti-inflammatory activity. However, specific details of in vivo efficacy studies, such as the animal models used and the dosing regimens, are not extensively detailed in the available literature. The compound is a natural product with potential therapeutic applications.
|
| Enzyme Assay |
The in vitro antioxidant activity of arjunolic acid is typically assessed using cell-free assays such as the DPPH radical scavenging assay. These assays measure the compound's ability to scavenge free radicals. Other assays such as ABTS, FRAP, or ORAC can also be used to assess its antioxidant capacity. These cell-free assays provide a measure of the compound's antioxidant potential.
|
| Cell Assay |
In vitro cellular assays for arjunolic acid assess its effects on cell viability, oxidative stress, and inflammation. Cells are treated with arjunolic acid and then exposed to an oxidative or inflammatory insult. Markers of oxidative stress and inflammation are measured. These assays demonstrate the compound's cytoprotective and anti-inflammatory effects in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for arjunolic acid have been conducted in models of chemical-induced organ pathophysiology to assess its protective effects. Its cardioprotective effects have also been studied. However, specific details of these studies are not extensively detailed in the available literature. The compound is a natural product with potential for further research.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for arjunolic acid are not extensively detailed in the available literature. As a natural triterpenoid, its oral bioavailability may be limited. However, its in vivo efficacy suggests that it reaches sufficient systemic concentrations to exert its effects. The compound's pharmacokinetic properties would be important for its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for arjunolic acid are not extensively detailed in the available literature. As a natural product with a long history of use in traditional medicine, it is generally considered to have low toxicity. However, comprehensive toxicological studies would be required to establish its safety profile for therapeutic use. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Arjunoic acid is a pentacyclic triterpenoid compound, a product of oleanolic-12-en-28-acid with hydroxyl groups at positions 2, 3, and 23 (2α,3β stereoisomers). It was isolated from hawthorn (Symplocos lancifolia) and walnut (Juglans sinensis) and possesses antioxidant and antibacterial activities. It functions as a metabolite, antibacterial agent, antifungal agent, and antioxidant. It is a pentacyclic triterpenoid compound and a hydroxy monocarboxylic acid derived from the hydride of oleanolic acid. Arjunoic acid has been reported to exist in larch (Lophostemon confertus), elm (Ulmus pumila), and several other organisms with relevant data.
Arjunolic acid is a pentacyclic triterpenoid found in Terminalia arjuna with diverse biological activities, including antioxidant, anticancer, anti-inflammatory, and cardioprotective properties. It is a potent antioxidant that protects cells and tissues from oxidative stress. It is a research compound with potential for studying oxidative stress, inflammation, and cardiovascular protection. It is not approved for clinical use. |
| Molecular Formula |
C30H48O5
|
|---|---|
| Molecular Weight |
488.69912
|
| Exact Mass |
488.35
|
| CAS # |
465-00-9
|
| PubChem CID |
73641
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
606.0±55.0 °C at 760 mmHg
|
| Flash Point |
334.3±28.0 °C
|
| Vapour Pressure |
0.0±3.9 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
6.51
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
35
|
| Complexity |
941
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)(C[C@H]([C@@H]([C@@]3(C)CO)O)O)C
|
| InChi Key |
RWNHLTKFBKYDOJ-DDHMHSPCSA-N
|
| InChi Code |
InChI=1S/C30H48O5/c1-25(2)11-13-30(24(34)35)14-12-28(5)18(19(30)15-25)7-8-22-26(3)16-20(32)23(33)27(4,17-31)21(26)9-10-29(22,28)6/h7,19-23,31-33H,8-17H2,1-6H3,(H,34,35)/t19-,20+,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~204.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0462 mL | 10.2312 mL | 20.4625 mL | |
| 5 mM | 0.4092 mL | 2.0462 mL | 4.0925 mL | |
| 10 mM | 0.2046 mL | 1.0231 mL | 2.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
